<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59003</article-id><article-id pub-id-type="doi">10.26442/00403660.2019.06.000281</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modern approaches to the detection of monoclonal gammopathy of undetermined significance (MGUS) in patients with kidney diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Современные подходы к выявлению моноклональной гаммапатии неопределенного значения (MGUS) у больных с поражением почек</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlovskaya(Lysenko)</surname><given-names>L. V</given-names></name><name xml:lang="ru"><surname>Козловская(Лысенко)</surname><given-names>Лидия Владимировна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chebotareva</surname><given-names>N. V</given-names></name><name xml:lang="ru"><surname>Чеботарева</surname><given-names>Наталья Викторовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»; тел.: +7(905)543-42-50; e-mail: natashatcheb@mail.ru; ORCID: 0000-0003-2128-8560</p></bio><email>natasha_tcheb@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mrykhin</surname><given-names>N. N</given-names></name><name xml:lang="ru"><surname>Мрыхин</surname><given-names>Николай Николаевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач клинической лабораторной диагностики, кабинет лабораторных исследований Университетской клинической больницы №3 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rameev</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Рамеев</surname><given-names>Вилен Вилевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Androsova</surname><given-names>T. V</given-names></name><name xml:lang="ru"><surname>Андросова</surname><given-names>Татьяна Витальевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Roshchupkina</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Рощупкина</surname><given-names>Светлана Васильевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>зав. отд-нием нефрологии клиники нефрологии, внутренних болезней и ревматологии Университетской клинической больницы №3 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова»</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Maryina</surname><given-names>S. A</given-names></name><name xml:lang="ru"><surname>Марьина</surname><given-names>Салия Ахсановна</given-names></name></name-alternatives><bio xml:lang="ru"><p>руководитель группы гуморального иммунитета ФГБУ «НМИЦ гематологии»</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kogarko</surname><given-names>I. N</given-names></name><name xml:lang="ru"><surname>Когарко</surname><given-names>Иветта Николаевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., в.н.с. отд. динамики химических и биологических процессов ФГБУН «Институт химической физики им. Н.Н. Семенова»</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kogarko</surname><given-names>B. S</given-names></name><name xml:lang="ru"><surname>Когарко</surname><given-names>Бронислав Станиславович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., в.н.с. отд. динамики химических и биологических процессов ФГБУН «Институт химической физики им. Н.Н. Семенова»</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University of the Ministry (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Research Center for Hematology of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Semenov Institute of Chemical Physics of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт химической физики им. Н.Н. Семенова» Российской академии наук</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2019</year></pub-date><volume>91</volume><issue>6</issue><issue-title xml:lang="en">VOL 91, NO6 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 91, №6 (2019)</issue-title><fpage>67</fpage><lpage>72</lpage><history><date date-type="received" iso-8601-date="2021-01-22"><day>22</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/59003">https://ter-arkhiv.ru/0040-3660/article/view/59003</self-uri><abstract xml:lang="en"><p>Monoclonal gammopathy (MG) is not only the state preceding of hematological neoplasms, but also associated with non - hematological diseases, in particular kidney damage. Aim. To assess the diagnostic value of “Freelite” methods in addition to electrophoresis (EF) and immunofixation (IF) of serum and urine proteins for detecting MG in patients with kidney diseases. Materials and methods. 87 patients with kidney damage, in which MG was established using the method of electrophoresis of serum proteins (EF), immunofixation (IF) and the method of free light chains determination - FLC “Freelite” were selected. The diagnostic value of three - component serum panel was compared with EF and IF. Results and discussion. AL-amyloidosis with kidney involvement was diagnosed in 41% patients, cryoglobulinemic glomerulonephritis (cryo GN) - in 18%, chronic glomerulonephritis (CGN) - in 35%, also there was small number of patients with light chain disease and cast - nephropathy. Determination of MG using EP was possible only in 38 (44%). Adding to the serum electrophoretic methods instead of the “Freelite” method, the urine EF and IF reduced the number of missed patients with monoclonal gammopathy from 24 (27%) to 11 (13%), including in the subgroup of patients with AL-amyloidosis but did not reach the sensitivity of the three - component serum screening panel. In 10 (11.5%) MG was represented only by intact mIg with one type of light chain, either κ or λ. Most often - in 25% of patients, intact monoclonal gammopathy was observed in HCV (+) cryo GN. A combination of intact mIgM, mIgG or mIgA with mFLC, was detected in 37 (42.5%). In almost half (46%) of the patients, only mFLC was detected - an abnormal κ/λ ratio. Conclusion: The serum screening panel EF + IF + “Freelite” spreads the low - grade monoclonal gammopathy recognition (MGUS) and should be included in the algorithm of examining patients with kidney disease.</p></abstract><trans-abstract xml:lang="ru"><p>Моноклональная гаммапатия (МГ) неопределенного значения (MGUS) является не только предопухолевым состоянием, предшествующим развитию множественной миеломы (ММ) и других секретирующих опухолей, но и возможной причиной заболеваний неопухолевой природы, в том числе поражения почек Цель исследования. Оценить информативность методов «Freelite», в добавление к электрофорезу (ЭФ) и иммунофиксации (ИФ) белков сыворотки и мочи, для выявления МГ у больных с поражением почек. Материалы и методы. Из 113 больных с МГ было отобрано 87 больных с поражением почек, у которых МГ установлена при использовании метода ЭФ белков сыворотки, ИФ и метода определения свободных легких цепей - FLC «Freelite». Проведена оценка эффективности в диагностике МГ этой трехкомпонентной сывороточной панели. Результаты и обсуждение. Из 87 больных с поражением почек МГ была определена у 39 (45%) пациентов с AL-амилоидозом, 16 (18%) - с (HCV+) криоглобулинемическим гломерулонефритом (крио-ГН), 28 (32%) - с хроническим ГН (ХГН), 4 (4%) - с болезнью отложения легких цепей (БОЛЦ) с помощью трехкомпонентной скрининговой панели. Определение МГ с помощью ЭФ было возможным только у 38 (44%) больных. Добавление к сывороточным электрофоретическим методам вместо метода «Freelite» ЭФ и ИФ мочи уменьшило число пропущенных больных с моноклональной гаммапатией - в целом с 24 (27%) до 11 (13%), но не достигло чувствительности трехкомпонентной сывороточной скрининговой панели. У 10 (11,5%) пациентов МГ была представлена только интактными mIg с одним типом легких цепей - либо κ, либо λ. Наиболее часто - у 25% больных - интактная МГ наблюдалась при HCV(+) крио-ГН. У 37 (42,5%) пациентов выявлена комбинация интактных mIgM, mIgG или mIgA с mFLC. Почти у половины (46%) больных обнаружены только mFLC - анормальное отношение κ/λ. Заключение. Трехкомпонентная сывороточная скрининговая панель ЭФ+ИФ+«Freelite» расширяет возможности распознавания МГ малого объема (MGUS) и должна быть введена в алгоритм обследования больных нефрологического профиля.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Freelite</kwd><kwd>monoclonal gammopathy</kwd><kwd>immunofixation of proteins</kwd><kwd>“Freelite”</kwd><kwd>amyloidosis</kwd><kwd>chronic glomerulonephritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>моноклональная гаммапатия</kwd><kwd>метод иммунофиксации</kwd><kwd>амилоидоз</kwd><kwd>хронический гломерулонефрит</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Leung N, Bridoux F, Hutchison C.A, Nasr S.H, Cockwell P, Fermand J.P, Dispenzieri A, Song K.W, Kyle R.A; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi: 10.1182/ blood-2012-07-445304</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Parry H, Pratt G, Hutchison C. Monoclonal gammopathy of undetermined significance: an update for nephrologists. Adv Chron Kidney Dis. 2012;19(5):291-6. doi: 10.1053/j.ackd.2012.07.006</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nasr S.H, Satoskar A, Markowitz G.S, Valeri A.M, Appel G.B, Stokes M.B, Nadasdy T, D'Agati V.D. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055-64. doi: 10.1681/ASN.2009010110</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bridoux F, Leung N, Hutchison C.A, Touchard G, Sethi S, Fermand J.P, Picken M.M, Herrera G.A, Kastritis E, Merlini G, Roussel M, Fervenza F.C, Dispenzieri A, Kyle R.A, Nasr S.H; International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711. doi: 10.1038/ki.2014.408</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hogan J.J, Weiss B.M. Bridging the divide: an onco - nephrologic approach to the monoclonal gammopathies of renal significance. Clin J Am Soc Nephrol. 2016;11(9):1681-91. doi: 10.2215/CJN.03160316</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon J.M, Ronco P, Touchard G, Bridoux F. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy - associated C3 glomerulopathy. Blood. 2017;129(11):1437-47. doi: 10.1182/blood-2016-08-737163</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Willrich M.A.V, Murray D.L, Kyle R.A. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem. 2018;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Katzmann J.A, Kyle R.A, Benson J, Larson D.R, Snyder M.R, Lust J.A, Rajkumar S.V, Dispenzieri A. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517-22. doi: 10.1373/clinchem.2009.126664</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Dispenzieri A, Kyle R, Merlini G, Miguel J.S, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau J.L, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos M.V, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar S.V, Durie B.G; International Myeloma Working Group. International Myeloma Working Group guidelines for serum - free light chain analysis in multiple myeloma and related disorders. Leukemia. 209;23:215-24. doi: 10.1038/leu.2008.307</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dimopoulos M, Kyle R, Fermand J.P, Rajkumar S.V, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson K.C, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi N.C, Jagannath S; International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701-5. doi: 10.1182/blood-2010-10-299529</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hill P.G, Forsyth J.M, Rai B, Mayne S. Serum free light chains: an alternative test to urine Bence Jones proteins when screening for monoclonal gammopathies. Clin Chem. 2006;52:1743-8. doi: 10.1373/clinchem.2006.069104</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jenner E. Serum free light chains in clinical laboratory diagnostics. Clin Chim Acta. 2014;427:15-20. doi: 10.1016/j.cca.2013.08.018</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani M.S, Melzi D'Eril G.V, Moratti R, Merlini G. Identification of amyloidogenic light chains requires the combination of serum - free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499-504. doi: 10.1373/clinchem.2008.117143</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Katzmann J.A, Dispenzieri A, Kyle R.A, Snyder M.R, Plevak M.F, Larson D.R, Abraham R.S, Lust J.A, Melton L.J 3rd, Rajkumar S.V. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575-8. doi: 10.4065/81.12.1575</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hutchison C, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol. 2009;5:621-7. doi: 10.1038/nrneph.2009.151</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Katzmann J.A, Clark R.J, Abraham R.S, Bryant S, Lymp J.F, Bradwell A.R, Kyle R.A. Serum reference intervals and diagnostic ranges for free and free immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-44. PMID: 12194920</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dispenzieri A, Katzmann J.A, Kyle R.A, Larson D.R, Melton L.J 3rd, Colby C.L, Therneau T.M, Clark R, Kumar S.K, Bradwell A, Fonseca R, Jelinek D.F, Rajkumar S.V. Prevalence and risk of progression of light - chain monoclonal gammopathy of undetermined significance: A retrospective population - based cohort study. Lancet. 2010;375:1721-8. doi: 10.1016/S0140-6736(10)60482-5</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Keeling J, Herrera G.A. Matrix metalloproteinases and mesangial remodeling in light chain - related glomerular damage. Kidney Int. 2005;68(4):1590-603. doi: 10.1111/j.1523-1755.2005.00571.x</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Basnayake K, Stringer S, Hutchison C, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79:1289-301. doi: 10.1038/ki.2011</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kapoulas S, Raptis V, Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrol Ther. 2015;11(3):135-43. doi: 10.1016/j.nephro.2014.12.005</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhu L, Herrera G.A, Murphy-Ullrich J.E, Huang Z.Q, Sanders P.W. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor - beta. Am J Pathol. 1995;147(2):375-85.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Russell W.J, Cardelli J, Harris E, Baier R.J, Herrera G.A. Monoclonal light chain - mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest. 2001;81:689-703.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Teng J, Russell W.J, Gu X, Cardelli J, Jones M.L, Herrera G.A. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84(4):440-51. doi: 10.1038/labinvest.3700069</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Keeling J, Teng J, Herrera G.A. AL-amyloidosis and light - chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84(10):1322-38.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Meri S, Koistinen V, Miettinen A, Tornroth T.G, Seppala I.J.T. Activation of the alternative pathaway of complement by monoclonal lambda L chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175:939-50.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Jokiranta T.S, Solomon A, Pangburn M.K, Zipfel P.F, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against factor H. J Immunol. 1999;163:4590-6.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Knight G.B, Gao L, Gragnani L, Elfahal M.M, De Rosa F.G, Gordon F.D, Agnello V. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryo - globulinemic vasculitis and B cell malignancies. Arthritis Rheum. 2010;62:2152-9. doi: 10.1002/art.27490</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Wang P.X, Sanders P.W. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol. 2007;18(4):1239-45. doi: 10.1681/ASN.2006111299</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Sethi S, Fervenza F.C, Rajkumar S.V. Spectrum of manifestations of monoclonal gammopathy - associated renal lesions. Curr Opin Nephrol Hypertens. 2016;25:127-37. doi: 10.1097/MNH.0000000000000201</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Zakharova E.V, Stolyarevich E.S, Vorobyeva O.A, Nikitin E.A Combined immunoglobulin G kappa nephropathy: Monoclonal immunoglobulin deposition disease and proximal tubulopathy: monoclonal gammopathy of renal significance or smoldering multiple myeloma? Case report and review of literature. Integr Cancer Sci Therap. 2017;4(1):1-9. doi: 10.15761/ICST.1000225</mixed-citation></ref></ref-list></back></article>
